ScienceDaily
•79% Informative
The 40 years of two studies have been presented at the European Society for Medical Oncology conference in Madrid.
The outcomes of these studies are going to revolutionize the landscape of bladder two cer treatment.
Traditionally, the European Society for Medical Oncology standard treatment fo Madrid der cancer patients who are able to tolerate this drug. NKI cisplatin ="summaryFeed_highLightText__NxlGi">John Haanen Myriam Chalabi NKI < the past years mm two Feed_highLightText__NxlGi">two Last year enfortumab vedotin ighLightText__NxlGi">two NKI Heijden Michiel van der d Heijden n> the Netherlands Cancer Institute Te NKI _NxlGi">2 US first mmaryFeed_highLightText__NxlGi">Netherlands Enfortumab Vedotin + pembrolizumab ESMO the New England Journal of Medicine 22% 901 CheckMate
VR Score
86
Informative language
90
Neutral language
63
Article tone
formal
Language
English
Language complexity
70
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links